Bladder cancer mortality after a diagnosis of nonmuscle-invasive bladder carcinoma

Papers of special note have been highlighted as: • of interest

References

• 1. Nielsen ME , Smith AB , Meyer A-M et al. Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the united states: 1988 to 2006. Cancer 120(1), 86–95 (2014).
  MedlineGoogle Scholar
• 2. Josephson DY , Pasin E , Stein JP . Superficial bladder cancer: part 1. Update on etiology, classification and natural history. Expert Rev. Anticancer Ther. 6(12), 1723–1734 (2006).
  MedlineGoogle Scholar
• 3. Smith ZL , Soloway MS . Expectant management of low-risk bladder cancer. Curr. Urol. Rep. 16(12), 82 (2015).
  MedlineGoogle Scholar
• 4. Erikson MS , Petersen AC , Andersen KK et al. National incidence and survival of patients with non-invasive papillary urothelial carcinoma: a danish population study. Scand. J. Urol. 52(5-6), 364–370 (2018).
  MedlineGoogle Scholar
• 5. Scosyrev E , Wu G , Golijanin D , Messing E . Non-bladder cancer mortality in patients with urothelial cancer of the bladder. Urol. Oncol. 31(5), 656–663 (2013).
  MedlineGoogle Scholar
• 6. Chang WC , Chang YH , Pan CC . Prognostic significance in substaging oft1 urinary bladder urothelial carcinoma on transurethral resection. Am. J. Surg. Pathol. 36(3), 454–461 (2012).
  MedlineGoogle Scholar
• 7. Pan C-C , Chang Y-H , Chen K-K , Yu H-J , Sun C-H , Ho DMT . Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am. J. Clin. Pathol. 133(5), 788–795 (2010).
  MedlineGoogle Scholar
• 8. Humphrey PA , Moch H , Cubilla AL , Ulbright TM , Reuter VE . The 2016 WHO classification of tumours of the urinary system and male genital organs – part B: prostate and bladder tumours. Eur. Urol. 70(1), 106–119 (2016).
  MedlineGoogle Scholar
• 9. Sylvester RJ , Van Der MA , Lamm DL . Intravesical bacillus Calmette–Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J. Urol. 168(5), 1964–1970 (2002).
  Medline CASGoogle Scholar
• 10. Witjes WP , Witjes JA , Oosterhof GO , Debruyne MJ . Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette–Guerin-Tice versus bacillus Calmette–Guerin RIVM in the treatment of patients with PTA-Pt1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Semin. Urol. Oncol. 14(1 Suppl. 1), 10–16 (1996).
  Medline CASGoogle Scholar
• 11. Amling CL . Diagnosis and management of superficial bladder cancer. Curr. Probl. Cancer 25(4), 219–278 (2001).
  Medline CASGoogle Scholar
• 12. Lebret T , Bohin D , Kassardjian Z et al. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette–Guerin instillations. J. Urol. 163(1), 63–67 (2000). • This publication reviewed outcomes of patients with TaG3 disease.
  Medline CASGoogle Scholar
• 13. Shahin O , Thalmann GN , Rentsch C , Mazzucchelli L , Studer UE . A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette–Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J. Urol. 169(1), 96–100; discussion 100 (2003). • Reviewed the patterns of recurrence and survival for nonmuscle-invasive bladder cancer.
  Medline CASGoogle Scholar
• 14. Hurle R , Losa A , Manzetti A , Lembo A . Intravesical bacille Calmette–Guerin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology 54(2), 258–263 (1999).
  Medline CASGoogle Scholar
• 15. Margel D , Tal R , Golan S , Kedar D , Engelstein D , Baniel J . Long-term follow-up of patients with stage T1 high-grade transitional cell carcinoma managed by bacille Calmette–Guerin immunotherapy. Urology 69(1), 78–82 (2007).
  MedlineGoogle Scholar
• 16. Abdel-Rahman O . Validation of the eighth AJCC new substages for bladder cancer among different staging contexts. Clin. Genitourin. Cancer 15(6), e1095–e1106 (2017).
  MedlineGoogle Scholar
• 17. Yee DS , Ishill NM , Lowrance WT , Herr HW , Elkin EB . Ethnic differences in bladder cancer survival. Urology 78(3), 544–549 (2011).
  MedlineGoogle Scholar
• 18. Fokdal L , Høyer M , Von Der Maase H . Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer. Acta Oncol. 43(8), 749–757 (2004).
  MedlineGoogle Scholar
• 19. Orré M , Latorzeff I , Fléchon A et al. Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer: a retrospective multicenter study. PLoS ONE 12(4), e0174978 (2017).
  MedlineGoogle Scholar
• 20. Resnick MJ , Bassett JC , Clark PE . Management of superficial and muscle-invasive urothelial cancers of the bladder. Curr. Opin. Oncol. 25(3), 281–288 (2013).
  Medline CASGoogle Scholar
• 21. Parekh DJ , Bochner BH , Dalbagni G . Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments. J. Clin. Oncol. 24(35), 5519–5527 (2006).
  MedlineGoogle Scholar
• 22. Hussain SA , Palmer DH , Syn W-K et al. Gene expression profiling in bladder cancer identifies potential therapeutic targets. Int. J. Oncol. 50(4), 1147–1159 (2017).
  Medline CASGoogle Scholar
• 23. Rosser CJ , Liu L , Sun Y et al. Bladder cancer-associated gene expression signatures identified by profiling of exfoliated urothelia. Cancer Epidemiol. Biomarkers Prev. 18(2), 444–453 (2009).
  Medline CASGoogle Scholar